About AF and cardiac ablationAF is the most common cardiac arrhythmia, and is a leading cause of stroke among people 65 years and older Worldwide it is estimated that 20 million people have AF, but only 100,000 are with ablation treated each year to the public. Health implications of AF are a growing concern, e who are at increased risk of morbidity and mortality and reduced quality of life with atrial fibrillation.
– executing the first case, Dr. Andrea Natale, Executive Medical Director of Texas Cardiovascular Arrhythmia Institute Medical Center St. , and a leading researcher said on this matter: ‘The THERMOCOO SmartTouch Catheter is a breakthrough technology in the field of electrophysiology. Provides provides me with new contact force information during AFib ablation. I look forward to a further evaluation of this technology in the SMART-AF study, ‘he concluded.. The THERMOCOO SmartTouch catheter is one of the most advanced catheter developed by Biosense Webster to date. During cardiac ablation process enables THERMOCOO SmartTouch catheter to measure the force and direction of catheter tip within the heart. This information is displayed graphically on a CART 3 Mapping and Navigation System, the most advanced 3D mapping system appears on the market, about the novel CART 3 Smart Touch Module, a fully integrated solution a fully integrated solution combining contact force and 3D mapping and navigation features.By the patient’s throat with a narcotic medicine, a tubular the width a straw drop that the nose spray in the pharynx or larynx. Surgeons use the laser fiber is through by this flexibility extent. The laser fires at and destroys abnormal tissue ignore normal tissues. You can larynx, the patient is coughing and stun at the medical spreads the necked, and minutes after it ‘s over, wrote Koufman.
Faculty for the international Conference consists known experts from Wake Forest Baptist and others from all over Europe and the United States. Next to Koufman and Postma and the other two course directors are Peter Dettmar, an associate research a professor at Voice centers , and Julian McGlashan, the University Hospital of, Queens Medical Centre, Nottingham, England.